Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor TypesGlobeNewsWire • 12/12/22
Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022GlobeNewsWire • 12/11/22
Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/10/22
Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022GlobeNewsWire • 11/03/22
Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/11/22
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 CongressGlobeNewsWire • 06/10/22
Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/12/22
Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 04/08/22
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 03/29/22
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 03/08/22
Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewsWire • 02/09/22
Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal CancersGlobeNewsWire • 02/03/22
Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter SyndromeGlobeNewsWire • 12/17/21
Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual MeetingGlobeNewsWire • 12/11/21
Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell LymphomaGlobeNewsWire • 12/07/21
Vincerx Pharma Hosting Key Opinion Leader Webinar on VIP152 Data Presented at the American Society of Hematology Annual MeetingGlobeNewsWire • 12/06/21
Vincerx Pharma Reports Third Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/12/21
Vincerx Pharma Announces Presentations at the American Society of Hematology Annual MeetingGlobeNewsWire • 11/04/21
Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/12/21
UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021GlobeNewsWire • 06/04/21
Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021GlobeNewsWire • 06/04/21